Therefore, platelet-targeted FXa gene therapy holds significant promise as an ideal alternative treatment for hemophilia patients, especially those who have developed anti-FVIII or anti-FIX inhibitors following replacement therapy. The gene discussed is F9; the disease is hemophilia.